ImmunoPrecise Antibodies (NASDAQ:IPA) Stock Price Up 15.5% – Time to Buy?

Posted by Alphonse Anthony on Jan 5th, 2025

Shares of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA – Get Free Report) were up 15.5% during mid-day trading on Friday . The company traded as high as $0.54 and last traded at $0.52. Approximately 1,246,779 shares traded hands during mid-day trading, an increase of 63% from the average daily volume of 766,140 shares. The stock had previously closed at $0.45.

Analysts Set New Price Targets

Separately, HC Wainwright dropped their price target on ImmunoPrecise Antibodies from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th.

View Our Latest Research Report on IPA

ImmunoPrecise Antibodies Trading Up 15.5 %

The company has a debt-to-equity ratio of 0.36, a current ratio of 1.01 and a quick ratio of 0.82. The firm has a market cap of $16.15 million, a price-to-earnings ratio of -0.67 and a beta of 0.06. The business’s 50-day moving average price is $0.42 and its two-hundred day moving average price is $0.65.

Institutional Investors Weigh In On ImmunoPrecise Antibodies

A hedge fund recently raised its stake in ImmunoPrecise Antibodies stock. Ingalls & Snyder LLC boosted its stake in ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA – Free Report) by 20.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,558,892 shares of the company’s stock after purchasing an additional 263,451 shares during the quarter. Ingalls & Snyder LLC owned about 5.41% of ImmunoPrecise Antibodies worth $996,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 6.70% of the company’s stock.

About ImmunoPrecise Antibodies

(Get Free Report)

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.